ANVS (STOCKS)
Annovis Bio, Inc.
$1.770000
-0.010000 (-0.56%)
Prev close: $1.780000
Company Information
- Exchange
- XNYS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Maria-Luisa Maccecchini
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $61.50M
- Employees
- 6
- P/E (TTM)
- -1.04
- P/B (TTM)
- 16.25
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
5
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.63 | $-0.40 | -0.2271 | -56.37% |
|
Dec 2025 (Q4)
|
$-0.39 | $-0.35 | -0.0398 | -11.36% |
|
Sep 2025 (Q3)
|
$-0.37 | $-0.31 | -0.0589 | -18.93% |
|
Jun 2025 (Q2)
|
$-0.32 | $-0.41 | +0.0906 | +22.07% |
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | $501.25K |
| Operating Expenses | $41.42M |
| Research and Development | $36.92M |
| Other Operating Expenses | $4.50M |
| Operating Income/Loss | -$41.42M |
| Income/Loss From Continuing Operations After Tax | -$40.92M |
| Income/Loss From Continuing Operations Before Tax | -$40.92M |
| Income Tax Expense/Benefit | $0.00 |
| Net Income/Loss | -$40.92M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$40.92M |
| Net Income/Loss Available To Common Stockholders, Basic | -$40.92M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.71 |
| Diluted Earnings Per Share | -$1.71 |
| Basic Average Shares | 68,695,105 |
| Diluted Average Shares | 68,695,105 |
| Assets | $16.24M |
| Current Assets | $16.24M |
| Noncurrent Assets | $0.00 |
| Liabilities | $13.12M |
| Current Liabilities | $12.79M |
| Accounts Payable | $5.28M |
| Wages | $734.34K |
| Other Current Liabilities | $6.78M |
| Noncurrent Liabilities | $327.00K |
| Equity | $3.13M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $3.13M |
| Liabilities And Equity | $16.24M |
| Net Cash Flow From Operating Activities | -$26.53M |
| Net Cash Flow From Operating Activities, Continuing | -$26.53M |
| Net Cash Flow From Investing Activities | $8.02M |
| Net Cash Flow From Investing Activities, Continuing | $8.02M |
| Net Cash Flow From Financing Activities | $18.52M |
| Net Cash Flow From Financing Activities, Continuing | $18.52M |
| Net Cash Flow | $0.00 |
| Net Cash Flow, Continuing | $0.00 |
| Comprehensive Income/Loss | -$40.92M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$40.92M |
| Other Comprehensive Income/Loss | $0.00 |